FDA 483 - John Heymach, M.D - November 05, 2021

An FDA inspection of John Heymach, M.D. in Houston, TX, identified a significant deviation from an investigational plan. The inspection revealed multiple instances where investigational product was infused into subjects at a faster rate than specified by the study protocol. This raises concerns regarding patient safety and drug efficacy.